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Abstract
Modifiable risk factors like obesity, hypertension, smoking, physical inactivity or atrial fibrillation account for a
significant proportion of the risk for ischaemic stroke, but genetic variation is also believed to contribute to the risk,
although few genetic risk variants were identified to date. Common clinical subtypes of stroke are caused by
cardiac embolism, large artery atherosclerosis and small cerebral vessel disease. Each of these underlying
pathologies may have a specific genetic architecture.
Previous genome-wide association studies (GWAS) showed association of variants near PITX2 and ZFHX3 with atrial
fibrillation and stroke. ANRIL (antisense Non-coding RNA in the INK4 Locus (harboring the CDKN2A/B genes))
variants were related to a variety of vascular diseases (myocardial infarction, aortic and intracranial aneurysm),
including ischaemic stroke. Now a recent GWAS published in Nature Genetics confirmed these previous
associations, analyzed the specificity of the previous associations with particular stroke subtypes and identified a
new association between HDAC9 and large vessel stroke. The findings suggest that well-recognized clinical stroke
subtypes correspond to distinct aetiological entities. However, the molecular pathways that are affected by the
identified genetic variants are not yet pinpointed, and the observed associations apply only for some, but not all
victims of a specific stroke aetiology.
Background
The International Stroke Genetics Consortium and the
Wellcome Trust Case Control Consortium 2 published
the largest genome-wide association study (GWAS) for
ischaemic stroke carried out to date [1]. Ischaemic stroke
is the second leading cause of death and the major cause
of long-term disability worldwide [2]. The risk for stroke
increases with age and with risk factors like cigarette
smoking, obesity, physical inactivity, hypertension, athero-
sclerosis, atrial fibrillation, a family history of stroke or a
previous stroke or TIA [3]. However, not all brain infarcts
are alike. Rather, they have multiple, sometimes compet-
ing, underlying aetiologies and subtypes. Five stroke sub-
types were defined according to the TOAST (Trial of Org
10172 in Acute Stroke Treatment) classification [4], using
clinical and diagnostic features: 1) large-artery athero-
sclerosis (large vessel disease, LVD), 2) cardioembolism
(CE), 3) small-vessel occlusion (small vessel disease, SVD),
4) stroke of other determined etiology (rare underlying
causes such as arterial dissection, inherited diseases of the
coagulation system or vasculitis), and 5) stroke of undeter-
mined etiology. Patients with LVD, SVD and CE stroke
subtypes have distinct symptoms, distinct risk profiles and
subtype-specific risks for recurrent events or events in first
degree relatives [5,6]. Stroke risk modification and stroke
prevention remain major items in health care. Primary
and secondary stroke prevention strategies differ according
to stroke subtype, for example, anticoagulation for cardi-
oembolic strokes, platelet inhibition for large vessel dis-
ease, antihypertensive treatment and statins for most
subtypes [6].
In some patients, despite extensive search, no underlying
causes are found and increasingly, we identify overlapping
etiologies, such as the combination of large vessel (carotid)
arteriosclerosis and atrial fibrillation as a potential source
of a cardioembolism. Even the subgroup LVD-stroke is
heterogeneous and far from being a simple homogeneous
phenotype. Many readers might feel that LVD mainly
refers to carotid bifurcation occlusive disease. However,
thrombogenic aortic disease, vertebrobasilar occlusive dis-
ease (which appears to be different from carotid disease),
distal carotid stenosis and intracranial occlusive disease
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(more frequent among Asians and Afro-Americans) are all
part of the LVD-definition.
Genetic association studies of ischaemic stroke
The identification of genetic variants that modify the risk
for stroke is still in its infancy. Inherited stroke syn-
dromes with identified disease-causing mutations exist,
but are rare [7]. The majority of strokes are thought to
be associated with a complex variety of interacting risk
factors, related to co-morbidities, life style, baseline char-
acteristics and genetic variants [8]. The impact of envir-
onmental and modifiable risk factors on stroke is well
recognized, albeit difficult to capture in its whole com-
plexity. On the contrary, modern genetic technologies
like high density single nucleotide polymorphism (SNP)
microarrays or second generation sequencing approaches
permit the precise, rapid and standardized documenta-
tion of a growing number of individual genetic variants -
at falling prices.
A GWAS is an observational study in which genetic
variation is compared between people with a parti-
cular condition (cases) and unaffected control indivi-
duals. Because genetic variants are assigned at
random from parents to offspring (Mendel’s law of
segregation) before birth (prospectively), a genetic
case control study can be thought of as a “natural”,
randomized controlled trial.
The GWAS technology is based on the popular
hypothesis that common diseases are associated with
common genetic variants [9]. However, GWAS results
probably explain only a few percent of the apparent
genetic variance contributing to common diseases [10].
Some limitations of the GWAS approach (lack of power
due to insufficient sample size, phenotypic heterogeneity)
may be solved, but others (only selected single nucleotide
variants with frequent alleles are genotyped) are intrinsic
to the microarray technology. It is to be expected that
other genetic techniques (whole exome sequencing stu-
dies or analysis of rare copy number variation [11]) will
identify other types of genetic variation (de novo muta-
tions, rare mutations, structural aberrations) that contri-
bute to the risk for stroke [12,13].
The currently published GWAS is a milestone in
stroke genetics for several reasons: it demonstrates the
power of very large multicenter study samples, advocates
the study of distinct stroke subtypes, replicates findings
of previous stroke GWAS and identifies a new asso-
ciated genetic variant. Moreover, the authors introduce
a statistical model to demonstrate the subtype-specificity
of the identified associations. Accordingly, the associa-
tion near the PITX2 and ZNFX3 genes was confirmed
to be specific for cardioembolic stroke, as to be expected
[14], since these variants were associated with atrial
fibrillation, a major risk factor for cardiac embolism.
The association of the ANRIL locus (chromosome 9p21
locus) with LVD seemed less specific. Indeed, alleles of
this locus were associated with a broad variety of vascu-
lar conditions, including myocardial infarction, type 2
diabetes mellitus, aortic aneurysm and intracranial
aneurysm [15,16].
SNP microarray studies start from the “common dis-
eases/common genetic variants” hypothesis. However,
the current GWAS study suggests that stroke genetics
develops towards the study of multiple distinct stroke
subtypes instead of a “common stroke” phenotype.
Future analysis of well defined stroke subtypes and of a
combination of multiple risk alleles [17] may lead to the
identification of high-risk multilocus genotype patterns,
but the population frequency of such allelic combina-
tions will be low. Hence, fragmentation of the stroke
phenotype into genetically homogeneous subtypes and
their association with specific genetic risk profiles may
lead away from the GWAS methodology and from the
“common disease/common genetic variants” hypothesis
towards the identification of personalized genetic blue-
prints as predictors of individual disease risks.
Conclusion
The currently published GWAS of ischaemic stroke
advocated the study of distinct stroke subtypes, repli-
cated findings of previous studies and identified a new
association between the A-allele of rs11984041 in
HDAC9 and ischaemic stroke caused by LVD. The
HDAC9 gene encodes histone deacetylase 9, which is
known to be involved in heart and muscle tissue devel-
opment. Carriers of the A-allele (about 9% of the study
population) have a 1.4 times increased risk for stroke
caused by LVD, and homozygous carriers (1% of the
population) have a two-fold risk. The underlying mole-
cular pathways explaining the association between
HDAC9 and large vessel stroke are currently unknown.
Further studies of common genetic variants in large
samples of patients with stroke subtypes or intermediate
phenotpyes and future analysis of rare genetic variants
may identify molecular pathways involved in stroke risk.
Recent GWAS findings, however, do not yet have direct
implications for stroke risk stratification [18,19].
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